George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Go Baby Go.
As they say you wouldn't get a team of such quality joining Poolbeg unless they saw massive potential.
New products with cash generation will shortly be brought in by Dave Allmond and collectively with that our other projects moving forward and a partnership deal signed for 001 will knock the lids off this. Revenue at this stage is key. We are in execution mode at the moment with news incoming any day.
I would say that CF is actively working on a reverse into Nasdaq which could bring in revenue generating products for us. Will we suffer dilution when this happens remains to be seen.
At the 37-minute mark, Paul Hill and John Hughman discuss HVO for about 5 minutes, and at 46mins POLB is discussed.
Great update.
https://www.youtube.com/watch?v=lDgZmvy6pdQ
It has been stated by JS that we have two different Pharmas interested in Polb 001 with one of them wanting to trial it later in the year in relation to Car-T treatment to combat the resulting Cytokine storm.
Surely this will result in a deal signed of some sort for exclusive partnership which is what Poolbeg Pharma want rather than in license to multiple parties. If it is an exclusive partnership the second party would if interested be under pressure to make their mind up if they want a slice of the cake.bThe structure of this deal is all guesswork to us stakeholders at the moment but it has been hinted that the preferred deal would be a single one covering all applications. We are adding different uses in order to make the partnership more valuable and more attractive for those nibbling at the hook.
I'm not sure how much new information we are really going to get from the annual results. An update on cash/burn rate etc, even that we can't really forecast going forward as we have little idea what the new Management team costs are, but apart from that, any update will be forward focused as there's no real revenue to speak about. The key information update is what's coming with POLB-001 partnership discussions and how close we are to agreement. Hopefully we are very close to a major deal to catapult the SP to multiples of the current price...
Didn't realise LSE is closed until Tuesday so I guess we will wait until then for annual results, happy Easter all,enjoy.
Buy sub 9 / 9.2,in the build phase.
Silverhorse, how's the Polb day trading going? You change your stance more than a Liberal Democrat MP.
Good end of the day backs to double digits on the ask. We could well get end of year results tomorrow if last year is anything to go by. It would be nice to get a cherry on top with the results. We shall see.
Results are a bit late, i feel no news middle of april, it will likely slip back to 9p on small sells so let it happen
MaryB, is your crystal ๐ฎ ball telling you to buy or sell today? ๐ค
Not interested in anything that TW^T has to say, I think MaryB talks more sense using a crystal ๐ฎ ball, lol ๐
No sign of the TW podcast yet from the other day.
No,crystal ball, just observation and risk management.
Within the spread, sub 9 works, 9/9.2 can get 9.08, 9/9.3 can get 9.21 etc. Never tempted to buy above 11p, a trim atm. Trim over 11 unreleased news propelling.
That's how I roll here, not a recommendation.
Still see this as a trebler so aiming for 800k shares at 6p average and then phase 2 is reduce that position sub zero by a sell above 12p.
๐ฎ
Well done, but if everyone did that they would be no buyers at the top and no sellers at the bottom. Does your crystal ๐ฎ ball give the sell price and the buy price on a daily basis?
Buy large Q low, 70%+ sell higher. Rinse, repeat Working a treat. Have more here than intended and average settling around 7p & falling nicely ๐.
Large late reported buy ยฃ23k
Silverhorse, if it's hits 40p, I'm move to Cote d'Azur !!!! It's definitely possible ! Big news must be coming soon !!!! Sit tight and hold !
we seem to get a fair few sellers when it gets close to 10p - so many times it falls back but no so sure this time its holding up well, am so certain its going big one way or another so holding firm for 40p plus or if the **** hits the fan 2p
Yes delighted but unexpected. Thought today was going to be red waiting for news. No news but must be bubbling under
Mmm..sudden about turn from recent drift downwards...is something brewing or another false dawn? ๐ค
I think Poolbeg Pharma has become what was previously "Open Orphan" (before it aquired Hvivo) ๐ค as a lot of emphasis on Orphan Drug Development, if you carefully read the article from 'Who is Poolbeg Pharma?' A lot said about becoming 'Amryt Pharma 2' but definitely'Open Orphan' as well. Both positive I suppose. JMO Adyor!
Poolbeg Pharma specialises in the development of innovative medicines to address critical unmet medical needs.
This includes cancer immunotherapy-induced CRS, infectious diseases and metabolic conditions such as obesity with the development of an oral GLP-1R agonist.
The company is also placing a growing emphasis on rare and orphan diseases.
Poolbeg is focused on commercialising approved and marketed drugs to fund the development of future ground-breaking products in the immunotherapy space.
The notice of allowance from the US Patent Office for a #POLB 001 patent featured in @SmallCaps_UK
The claims cover the treatment & prevention of cytokine storm after an immune response has been triggered - in any disease indication
https://smallcaps.co.uk/poolbeg-pharma-closer-granting-patent-polb-001-treat-multiple-diseases/